Overview
Lobbying Costs
250,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
1.5 Fte (6)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
The Health Policy Partnership (HPP)
EU Transparency Register
223430420230-66 First registered on 08 Jan 2016
Goals / Remit
We are a specialist health policy consultancy. We create innovative policy initiatives and powerful evidence–based communications for organisations across the health spectrum. We provide a unique, seamless approach to help resolve the most complex issues facing our health care systems. We do this through rigorous research and expert synthesis of evidence, inter-sectoral collaboration, and powerful communications that act as the starting point for meaningful changes in policy and practice.
Main EU files targeted
HPP is a member of the The EU Health Policy Platform (representing the HFPN). See: https://ec.europa.eu/health/interest_groups/policy_platform_en
Address
Head Office
The Health Policy Partnership
68-69 St Martin's Lane
London WC2N 4JS
UNITED KINGDOM -
People
Total lobbyists declared
6
Employment time Lobbyists 25% 6 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Time provided above relates to HPP staff time dedicated to any formal engagement with MEPs, EU officials, or where there is policy activity directly involving or targeting EU institutions - i.e. it excludes general health policy activities where other audiences are our primary targets (e.g. national policy makers, academic experts, clinicians, health providers etc), and global activities.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
I - Professional consultancies/law firms/self-employed consultants
Subcategory
Professional consultancies
-
Networking
Affiliation
Heart Failure Policy Network - www.hfpolicynetwork.eu
(provide secretariat and lead project)
Knowledge partner for the Coalition to Eradicate Viral Hepatitis from Asia Pacific (www.cevhap.org)Member organisations
Please see www.hfpolicynetwork.eu
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
250,000€
Other financial info
None declared
Declared lobby clients
Client Name Amount Advanced Accelerator Applications 200,000€ - 299,999€ ASTRA ZENECA 50,000€ - 99,999€ Curium 10,000€ - 24,999€ Novartis AG 25,000€ - 49,999€ Vifor Pharma 25,000€ - 49,999€ -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
HF POLICY NETWORK (HFPN)
HPP acts as Secretariat for the HF Policy Network, a multidisciplinary group of politicians from across Europe working with patients, health professionals and other stakeholders to lead significant policy changes that may improve the lives of people with heart failure (HF).
The HFPN has ongoing relationships with several MEPs who donate their time for free to support (and act as Members of) the HFPN. In 2020, HFPN launched the "Heart failure policy and practice in Europe" project. The project aims to support advocates with a clear outline of policy issues and best practice in heart failure across 11 European countries. A virtual launch, supported by Billy Kelleher MEP, was on the 9 December 2020.
RADIOLIGAND THERAPY
HPP established a multi-stakeholder steering committee comprising patient advocates and experts in oncology and nuclear medicine from across Europe, to develop a policy report to raise awareness of radioligand therapy as an innovative component of cancer care. Through desk research and interviews with additional stakeholders, the report was drafted to reflect the consensus of the steering committee.
Alongside the main report, HPP created an animated video on radioligand therapy, to explain this complex process to a wider audience. We also created a two-page report summary featuring a top-line explanation of radioligand therapy and a distillation of the report’s recommended actions to overcome barriers to integration of radioligand therapy in clinical cancer care.
The report and other outputs were launched during an event at the European Parliament in Brussels on Wednesday 22 January 2020, which was co-hosted by Tanja Fajon MEP and Ewa Kopacz MEP. This was the first European-level policy meeting on radioligand therapy.Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 25 Oct 2023 Location Brussels, Belgium Subject Role of the EU in promoting heart health Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Katherine Power (Cabinet member)